Sharareh Seifi
Overview
Explore the profile of Sharareh Seifi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seifi S, Esfahanimonfared Z, Khosravi A, Moeini Nia F
Cureus
. 2025 Jan;
16(12):e75710.
PMID: 39811219
Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience disease recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify patients at risk of early relapse,...
2.
Salimi B, Seifi S, Khosravi A, Shiari S, Moradi R, Daneshfard B, et al.
Arch Iran Med
. 2024 Oct;
27(9):501-507.
PMID: 39465525
Background: Lung cancer (LC) is one of the leading causes of cancer-related deaths worldwide. In Iran, it is the second most common cause of cancer-related deaths for men and the...
3.
Jahani M, Mashayekhi P, Omrani M, Khosravi A, Ali D, Azad Manjiri S, et al.
Iran Biomed J
. 2024 Sep;
28(4):208-15.
PMID: 39289877
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy...
4.
Seifi S, Fakhrai G, Esfahani-Monfared Z, Khosravi A, Abedini A, Salimi B, et al.
Tanaffos
. 2024 Aug;
22(4):411-417.
PMID: 39176146
Background: Lung cancer is the leading cause of cancer death. Among different lung cancer histopathologies, small cell lung cancer (SCLC) has been known to be the most aggressive and lethal...
5.
Mirshahvalad S, Manafi-Farid R, Fallahi B, Seifi S, Geramifar P, Emami-Ardekani A, et al.
Nucl Med Commun
. 2023 Jun;
44(9):803-809.
PMID: 37334548
Objective: In this study, we aimed to compare the diagnostic value of [ 68 Ga]Ga-Pentixafor and [ 18 F]FDG PET/CT in the evaluation of non-small cell lung cancer (NSCLC) patients....
6.
Mirtavoos-Mahyari H, Abbasi Dezfouli A, Esfahani-Monfared Z, Khosravi A, Seifi S, Sheikhy K
Tanaffos
. 2023 Apr;
21(3):376-383.
PMID: 37025321
Background: Activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to tyrosine kinase inhibitors (TKIs), but responses to TKIs is not permanent and drug resistance eventually happens...
7.
Seifi S, Salimi B, Monfared Z, Sabahi C, Kafi H, Khosravi A
J Pharm Policy Pract
. 2023 Jan;
16(1):16.
PMID: 36698207
Background: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung...
8.
Dezfuli N, Adcock I, Alipoor S, Salimi B, Seifi S, Chehrazi M, et al.
Tanaffos
. 2022 Oct;
21(1):15-23.
PMID: 36258913
Background: Globally, lung cancer represents a major cause of cancer-related deaths. The regulation of gene expression is modulated by small noncoding RNAs called miRNAs that can act as both tumor...
9.
Shahriari S, Seifi S, Khodakarim N, Ramim T, Dashtpeima A
Med J Islam Repub Iran
. 2022 Sep;
36:31.
PMID: 36128277
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib have shown promising efficacy and tolerability in patients with advanced NSCLC. Identifying subgroups of patients who benefit...
10.
Jenabian A, Ehsanpour A, Mortazavizadeh S, Raafat J, Razavi M, Khosravi A, et al.
Support Care Cancer
. 2022 Jul;
30(10):8151-8158.
PMID: 35792924
Purpose: Phase IV clinical trials are required to evaluate the real-world safety and effectiveness of drugs. This study aimed to evaluate the safety and effectiveness of once-per-cycle administration of PegaGen...